BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 34919784)

  • 1. Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma.
    Martins EP; Gonçalves CS; Pojo M; Carvalho R; Ribeiro AS; Miranda-Gonçalves V; Taipa R; Pardal F; Pinto AA; Custódia C; Faria CC; Baltazar F; Sousa N; Paredes J; Costa BM
    Mol Oncol; 2022 Jul; 16(14):2611-2631. PubMed ID: 34919784
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Gonçalves CS; Vieira de Castro J; Pojo M; Martins EP; Queirós S; Chautard E; Taipa R; Pires MM; Pinto AA; Pardal F; Custódia C; Faria CC; Clara C; Reis RM; Sousa N; Costa BM
    Theranostics; 2018; 8(17):4805-4823. PubMed ID: 30279739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of PSMD family members and validation of PSMD9 as a potential therapeutic target in human glioblastoma.
    Li Y; Liu X; Zhao F; Zhao Z; Li X; Wang J; Huang B; Chen A
    CNS Neurosci Ther; 2024 Feb; 30(2):e14366. PubMed ID: 37485655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel molecular link between HOXA9 and WNT6 in glioblastoma identifies a subgroup of patients with particular poor prognosis.
    Gonçalves CS; Xavier-Magalhães A; Martins EP; Pinto AA; Pires MM; Pinheiro C; Reis RM; Sousa N; Costa BM
    Mol Oncol; 2020 Jun; 14(6):1224-1241. PubMed ID: 31923345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia-inducible miR-196a modulates glioblastoma cell proliferation and migration through complex regulation of NRAS.
    Takkar S; Sharma V; Ghosh S; Suri A; Sarkar C; Kulshreshtha R
    Cell Oncol (Dordr); 2021 Apr; 44(2):433-451. PubMed ID: 33469841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of GBP1 predicts poor prognosis and promotes tumor growth in human glioblastoma multiforme.
    Ji X; Zhu H; Dai X; Xi Y; Sheng Y; Gao C; Liu H; Xue Y; Liu J; Shi J; Zhang Y; Chen Y; Dai X; Li M; Wang A; Dong J
    Cancer Biomark; 2019; 25(3):275-290. PubMed ID: 29991124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and prognostic significance of TCTN1 in human glioblastoma.
    Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D
    J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cadherin-11, a marker of the mesenchymal phenotype, regulates glioblastoma cell migration and survival in vivo.
    Kaur H; Phillips-Mason PJ; Burden-Gulley SM; Kerstetter-Fogle AE; Basilion JP; Sloan AE; Brady-Kalnay SM
    Mol Cancer Res; 2012 Mar; 10(3):293-304. PubMed ID: 22267545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental-Cadherin, a biomarker for local immune status and poor prognosis among patients with tongue squamous cell carcinoma.
    Wang H; Yu T; Mao L
    Eur Arch Otorhinolaryngol; 2022 Jul; 279(7):3597-3609. PubMed ID: 34825969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic potential of PIK3CD in glioblastoma is exerted through cytoskeletal proteins PAK3 and PLEK2.
    Shao W; Azam Z; Guo J; To SST
    Lab Invest; 2022 Dec; 102(12):1314-1322. PubMed ID: 35851857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NFкB is a critical transcriptional regulator of atypical cadherin FAT1 in glioma.
    Srivastava C; Irshad K; Gupta Y; Sarkar C; Suri A; Chattopadhyay P; Sinha S; Chosdol K
    BMC Cancer; 2020 Jan; 20(1):62. PubMed ID: 31992226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-663 Suppresses Oncogenic Function of CXCR4 in Glioblastoma.
    Shi Y; Chen C; Yu SZ; Liu Q; Rao J; Zhang HR; Xiao HL; Fu TW; Long H; He ZC; Zhou K; Yao XH; Cui YH; Zhang X; Ping YF; Bian XW
    Clin Cancer Res; 2015 Sep; 21(17):4004-13. PubMed ID: 26023083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of matrix metalloproteinase-2 and -9, ADAM-10 and N-cadherin expression in human glioblastoma multiforme.
    Musumeci G; Magro G; Cardile V; Coco M; Marzagalli R; Castrogiovanni P; Imbesi R; Graziano AC; Barone F; Di Rosa M; Castorina S; Castorina A
    Cell Tissue Res; 2015 Oct; 362(1):45-60. PubMed ID: 25948484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma.
    Jeong HY; Kim HJ; Kim CE; Lee S; Choi MC; Kim SH
    Int J Neurosci; 2021 Jan; 131(1):7-14. PubMed ID: 32075484
    [No Abstract]   [Full Text] [Related]  

  • 16. Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene.
    Mala U; Baral TK; Somasundaram K
    BMC Cancer; 2022 Jun; 22(1):642. PubMed ID: 35690717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actin-Binding LIM 1 (ABLIM1) Inhibits Glioblastoma Progression and Serves as a Novel Prognostic Biomarker.
    Liu D; Wang X; Liu Y; Li C; Zhang Z; Lv P
    Dis Markers; 2022; 2022():9516808. PubMed ID: 36583064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.
    Thota B; Arimappamagan A; Kandavel T; Shastry AH; Pandey P; Chandramouli BA; Hegde AS; Kondaiah P; Santosh V
    J Neurosurg; 2014 Aug; 121(2):374-83. PubMed ID: 24878287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas.
    Han MZ; Xu R; Xu YY; Zhang X; Ni SL; Huang B; Chen AJ; Wei YZ; Wang S; Li WJ; Zhang Q; Li G; Li XG; Wang J
    J Exp Clin Cancer Res; 2017 Nov; 36(1):155. PubMed ID: 29110682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation.
    Paredes J; Albergaria A; Oliveira JT; Jerónimo C; Milanezi F; Schmitt FC
    Clin Cancer Res; 2005 Aug; 11(16):5869-77. PubMed ID: 16115928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.